In a review of recently published scientific studies, investigators at Keck School of Medicine of USC identified a natural barrier to the inner’s sensory cells’ ability to regenerate.
AstraZeneca Plc’s drug Lynparza reduced the risk of relapse and death in breast cancer patients with certain mutations in a late-stage trial, the British drugmaker said on June 3.
Artios Pharma entered into a global research collaboration with Novartis for the purpose of discovering and validating next-generation DNA damage response (DDR) targets and enhancing Novartis’ radioligand therapies.
The European Medicines Agency (EMA) recommended approval for Lynparza in patients with a form of prostate cancer and as a first-line maintenance treatment for a form of advanced ovarian cancer, the British drugmaker AstraZeneca said.
The U.S. Food and Drug Administration approved FoundationOne Liquid CDx, a new pan-tumor liquid biopsy test that is indicated for use as a companion diagnostic for four FDA-approved precision therapies.
The U.S. Food and Drug Administration approved Clovis Oncology Inc.’s drug Rubraca for the treatment of adult patients with metastatic castration-resistant prostate cancer, whose tumors have a genetic mutation.
U.S. FDA Approves Rubraca as Monotherapy Treatment for mCRPCAccelerated Approval, Acute Myeloid Leukemia (AML), Androgen Receptor-Directed Therapy, Approvals, BRCA Mutation-Associated Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemotherapy, FDA, FDA/Regulatory, Myelodysplastic Syndromes, New Indications, PARP Inhibitors, Supplemental New Drug Application (sNDA), Taxane-Based Chemotherapy
The U.S. Food and Drug Administration approved Clovis Oncology Inc.’s Rubraca (rucaparib) tablets for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.
The U.S. Food and Drug Administration approved AstraZeneca and Merck’s Lynparza (olaparib) in combination with Roche’s Avastin (bevacizumab) for the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer has been tested to have either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.
The U.S. Food and Drug Administration cleared expanded use of GlaxoSmithKline Plc’s Zejula as a first option to keep advanced ovarian cancer at bay in women who have responded to chemotherapy.
AstraZeneca and Merck’s Combo Therapy Flunks Late-Stage Ovarian Cancer TrialBRCA mutation, Business, Clinical Trials, Collaborations, Combination Therapies, DNA Damage Response (DDR), National Cancer Institute, NRG Oncology, PARP Inhibitors, Platinum-Sensitive Relapsed Ovarian Cancer, R&D, Vascular Endothelial Growth Factor (VEGF) Inhibitors
AstraZeneca and Merck announced that the Phase III GY004 trial of cediranib in combination with Lynparza compared to platinum-based chemotherapy in platinum-sensitive relapsed ovarian cancer failed to meet the primary endpoint.